ZP
TXG icon

Zimmer Partners’s 10x Genomics TXG Stock Holding History

Zimmer Partners’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-10,000
Closed -$763K – 106
2019
Q4 		$763K Hold
10,000
– – 0.01% 75
2019
Q3 		$504K Buy
+10,000
New +$553K 0.01% 100

Other funds holding TXG

FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
FCMI
Foresite Capital Management I Larkspur, California $21.4M AUM 80.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JCM
JS Capital Management New York $109M AUM 34.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Zimmer Partners's TXG Position: Q1 2020 in Review

Zimmer Partners sold out of 10x Genomics (TXG) in Q1 2020, closing a stake of 10,000 shares — an estimated $763K sold.

Zimmer Partners first reported a position in TXG in Q3 2019 and held it in 2 quarters. The position peaked at $763K in Q4 2019. 103 funds tracked by Wall St. Rank hold TXG as of Q1 2020.

  • Zimmer Partners reported no remaining 10x Genomics position as of Q1 2020 after selling out during the quarter.
  • Zimmer Partners sold 10,000 10x Genomics shares in Q1 2020, an estimated $763K.
  • Zimmer Partners first reported a position in 10x Genomics in Q3 2019 and held it in 2 quarters.
  • Zimmer Partners's 10x Genomics position peaked at $763K in Q4 2019.
  • 103 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2020.

Based on Zimmer Partners's 13F filing for Q1 2020, filed 15 May 2020.